DOCS.L

Dr. Martens plc
Dr. Martens PLC - Director/PDMR Shareholding
12th July 2024, 11:42
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2671W
Dr. Martens PLC
12 July 2024
 

Dr. Martens plc (the 'Company')

Director/PDMR Shareholding

Notification of Transaction by Director/Person Discharging Managerial Responsibility

The Company announces that it was notified on 12 July 2024 of the following transaction in the Company's Ordinary 1p shares undertaken by a director / person discharging managerial responsibility ('PDMRs') under the Company's Share Incentive Plan ('SIP').

The SIP is an HMRC approved, all-employee scheme under which participating employees are able to purchase shares in the Company from monthly salary ('Partnership Shares') and receive allocations of free 'Matching Shares', awarded at a rate of one Matching Share for every one Partnership Share purchased by a participating employee, from the Company.

 

On 12 July 2024, the following director / PDMR acquired Partnership Shares as a result of their participation in the SIP at a price of 75.00p pence per share and was granted an allocation of Matching Shares (for no consideration) in the quantity set out in the table below:

 

Director / PDMR

Number of Partnership Shares purchased

Number of
Matching Shares awarded

Kenny Wilson

200

200


The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Kenny Wilson

2

Reason for the notification

a)

Position/status

PDMR (Chief Executive Officer)

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Dr. Martens plc

b)

LEI

213800QPT8YM6NQZPH28

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of GBP 0.01


ISIN: GB00BL6NGV24

b)

Nature of the transaction

1.     Purchase of Partnership Shares under the SIP

2.     Award of Matching Shares under the SIP

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

1.

75.00p

200

2.

Nil

200

d)

Aggregated information

 

-

Aggregated volume

-

Price

 

 

-

Aggregated volume

-

Price

 

 

1.

Partnership shares


200


75.00p  

 

2.

Matching shares


200


Nil

e)

Date of the transaction

11 July 2024

f)

Place of the transaction

1.     London Stock Exchange (XLON)

2.     Outside of a trading venue

 

 

For further information please contact:

 

 

Rebecca Flaherty

Company Secretarial Assistant

+44(0)7570 309775           

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUUSARSRUBAAR]]>
TwitterFacebookLinkedIn